Indeed, all these analyses of human CML genomic samples confirm the critical role played by SOS1 in CML pathogenesis and support its consideration as a novel and additional molecular target for the design of future therapy approaches against this disease. The gene discussed is SOS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.